To hear about similar clinical trials, please enter your email below
Trial Title:
Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism
NCT ID:
NCT06130683
Condition:
Secondary Hyperparathyroidism
Conditions: Official terms:
Neoplasm Metastasis
Hyperparathyroidism
Hyperparathyroidism, Secondary
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Single-cell sequencing
Description:
Single-cell sequencing technology can reveal the gene structure and gene expression
status of individual cells, reflecting the heterogeneity between cells.
Arm group label:
Normal group
Arm group label:
Primary Hyperparathyroidism
Arm group label:
Secondary Hyperparathyroidism
Summary:
This project intends to select cases that meet the research requirements, take secondary
hyperparathyroidism, primary hyperparathyroidism and normal human parathyroid tissue, a
total of three groups, 4 cases in each group, through the method of single-cell
transcription and sequencing, construct a map of human parathyroid function types, reveal
the gene structure and gene expression status of cells, and visualize the expression
characteristics, intercellular heterogeneity, and heterogeneity of cell subsets of
secondary hyperparathyroid cells in a hierarchical manner, draw a single-cell map, and
compare the differences between groups. To explore the pathogenesis of secondary
hyperparathyroidism.
Secondary hyperparathyroidism, parathyroid tissue of primary hyperparathyroidism and
normal parathyroid tissue obtained by accident were collected, frozen and preserved,
frozen tissue thawed, single-cell suspension was prepared and each cell was specifically
labeled by the Mozhuo Genomics system, after oil breaking, polymerase chain reaction
amplification, reverse transcription to obtain complementary DNA, and a library of
complementary DNA that passed quality inspection was constructed to obtain high-quality
data of parathyroid cells. Cell Ranger, R Seurat package, and t-SNE dimensionality
reduction diagram were used to reduce the dimensionality, cluster, and visualize the
data.
In order to construct a single-cell atlas of parathyroid glands, investigators performed
cluster analysis of similar cells according to the gene expression profile, and then
visualized the data by t-SNE. According to the results of cell clustering, the specific
and highly expressed genes in each cell cluster were identified. Cell populations were
identified according to the expression of landmark genes, and the differences in cell
types and proportions between groups were compared.
Criteria for eligibility:
Study pop:
People who undertake surgery for secondary hyperparathyroidism or primary
hyperparathyroidism and other neck surgeries in our China-Japan Friendship Hospital
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Study participants with a diagnosis of secondary hyperparathyroidism who underwent
surgical treatment
- Study participants with a diagnosis of primary hyperparathyroidism who underwent
surgical treatment
- Study participants who have obtained informed consent
Exclusion Criteria:
- Other non-secondary hyperparathyroidism conditions such as primary
hyperparathyroidism were excluded at the time of inclusion of study participants
with essential hyperparathyroidism.
- Other non-primary hyperparathyroid conditions such as secondary hyperparathyroidism
were excluded at the time of inclusion of study participants with essential
hyperparathyroidism.
- Refusal of informed consent.
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
China and Japan Friendship Hospital
Address:
City:
Beijing
Country:
China
Status:
Recruiting
Contact:
Last name:
Meng Yang
Phone:
13651107012
Email:
mengyang7012@163.com
Start date:
November 8, 2023
Completion date:
July 31, 2025
Lead sponsor:
Agency:
China-Japan Friendship Hospital
Agency class:
Other
Source:
China-Japan Friendship Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06130683
